Sensitivity to BUB1B Inhibition Defines an Alternative Classification of Glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain cancer with limited treatment options.
• The mitotic spindle checkpoint molecule BUB1B is implicated in GBM progression and drug resistance.

Purpose of the Study:

• To investigate BUB1B as a predictive marker for GBM aggressiveness and drug response.
• To develop a computational framework for classifying GBM tumors based on BUB1B sensitivity.

Main Methods:

• Utilized gene expression data from GBM cells and neural progenitor cells.
• Developed a computational framework to predict BUB1B inhibition sensitivity.
• Stratified patient tumors into BUB1B-sensitive (BUB1B ^S) and BUB1B-resistant (BUB1B ^R) subtypes.
• Performed functional genomic profiling and drug sensitivity assays.

Main Results:

• BUB1B ^S GBM patients exhibited a significantly worse prognosis across all tumor subtypes.
• Identified differential gene reliance in BUB1B ^S and BUB1B ^R GBM isolates, particularly in cell cycle and chromosome segregation pathways.
• Predicted and validated increased sensitivity of BUB1B ^S cells to topoisomerase and Raf inhibitors.

Conclusions:

• The BUB1B ^R/S classification effectively predicts GBM clinical course and response to specific drug treatments.
• BUB1B serves as a valuable predictive biomarker for glioblastoma multiforme treatment strategies.